Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome

Blood

Volumn 98, Issue 8, 2001, Pages 2466-2473

  Blessing, Jack J H ^a,b   Brown, Margaret R ^a   Straus, Stephen E ^a   Dale, Janet K ^a   Siegel, Richard M ^a   Johnson, Michele ^a   Lenardo, Michael J ^a   Puck, Jennifer M ^a   Fleisher, Thomas A ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b ARKANSAS CHILDREN S HOSPITAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE MUTATION; GENOTYPE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPHENOTYPING; LYMPHOCYTE SUBPOPULATION; LYMPHOPROLIFERATIVE DISEASE; MALE; PENETRANCE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0035889162     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.8.2466     Document Type: Article

References (45)

1. Lenardo M, Chan FKM, Hornung F, et al. Mature T lymphocyte apoptosis - immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol. 1999;17:221-252.
2. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992;356:314-317.
3. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 1994;76:969-976.
4. Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr. 1967;70:891-899.
5. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science.1995;268:1347-1349.
6. Sneller MC, Straus SE, Jaffe ES, et al. A novel lymphoproliferative/autoimmune syndrome resembling murine Ipr/gld disease. J Clin Invest. 1992;90:334-341.
7. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human lymphoproliferative syndrome. Cell. 1995;81:935-946.
8. Drappa J, Vaishnaw AK, Sullivan KE, Chu J-L, Elkon KB. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med. 1996;335:1643-1649.
9. Bettinardi A, Brugnoni D, Quiros-Roldan E, et al. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood. 1997;89:902-909.
10. Puck JM, Straus SE, Le Deist F, Rieux-Laucat F, Fischer A. Inherited disorders with autoimmunity and defective lymphocyte regulation. In: Ochs HD, Edvard Cl, Puck JM, eds, Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. New York: Oxford University Press; 1998:339-352.
11. Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med. 1999;130:591-601.
12. Lim MS, Straus SE, Dale JK, et al. Pathological findings in human autoimmune lymphoproliferative syndrome. Am J Pathol. 1998;153:1541 -1550.
13. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest. 1996;98:1107-1113.
14. Pan ZQ, Atkinson TP, Atkinson TP, Makris CM, Cooper MD, McDonald JM. ALPS (autoimmune lymphoproliferative syndrome) associated with a mutation in Fas-Ligand [abstract]. Clin Immunol. 1999;90:442.
15. Wang J, Zheng L, Lobito A, et al. Inherited human caspase-10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome, type II. Cell. 1999;98:47-58.
16. Dianzani U, Bragardo M, DiFranco D, et al. Deficiency of the Fas apoptosis pathway without Fas gene mutations in pediatric patients with autoimmune/lymphoproliferation. Blood. 1997;89:2871-2879.
17. Sneller MC, Wang J, Dale JK, et al. Clinical, immunologic and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood. 1997;89:1341-1348.
18. Jackson CE, Fischer RE, Hsu AP, et al. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance. Am J Hum Genet. 1999;64:1002-1014.
19. Fuss IJ, Strober W, Dale JK, et al. Characteristic T helper 2 T cell cytokine abnormalities in autoimmune lymphoproliferative syndrome marked by defective apoptosis and humoral autoimmunity. J Immunol. 1997;158:1912-1918.
20. Erkeller-Yuksel FM, Deneys V, Yuksel B, et al. Age-related changes in human blood lymphocyte populations. J Pediatr. 1992;120:216-222.
21. Vaishnaw AK, Orlinick JR, Chu JL, Krammer PH, Chao MV, Elkon KB. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J Clin Invest. 1999;103:355-363.
22. Rieux-Laucat F, Blanchère S, Danielan S, et al. Lymphoproliferative syndrome with autoimmunity: a possible genetic basis for dominant expression of the clinical manifestations. Blood. 1999;94:2575-2582.
23. Peng SL, Madaio MP, Hayday AC, Craft J. Propagation and regulation of systemic autoimmunity by γδ T cells. J Immunol. 1996;157:5689-5698.
24. Reap EA, Piecyk ML, Oliver A, et al. Phenotypic abnormalities of splenic and bone marrow B cells in Ipr and gld mice. Clin Immunol Immunopathol. 1996;78:21-29.
25. Davidson WF, Giese T, Fredrickson TN. Spontaneous development of plasmacyloid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med. 1998;187:1825-1838.
26. Reap EA, Sobel ES, Cohen PL, Eisenberg RA. Conventional B cells, not B-1 cells, are responsible for producing autoantibodies in Ipr mice. J Exp Med. 1993;177:69-73.
27. Theofilopoulos AN, Dixon FJ. Murine models of systemic lupus erythematosus. Adv Immunol. 1985;37:269-290.
28. Jackson CE, Puck JM. Autoimmune lymphoproliferative syndrome, a disorder of apoptosis. Curr Opin Pediatr. 1999;11:521-527.
29. Ishida H, Hastings R, Kearney J Howard M. Continuous anti-interleukin 10 antibody administration depletes mice of Ly-1 B cells but not conventional B cells. J Exp Med. 1992;175:1213-1220.
30. Levy Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest. 1994;93:424-428.
31. Kitabayashi A, Hirokawa M, Miura AB. The role of interleukin-10 (IL-10) in chronic B-lymphocytic leukemia: IL-10 prevents leukemic cells from apoptotic cell death. Int J Hematol. 1995;2:99-106.
32. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW. Interleukin-2 receptor a chain regulates the size and content of the peripheral lymphoid compartment. Immunity. 1995;3:521-530.
33. Van Parijs L, Biuckians A, Ibragimov A, Alt FW, Willerford DM, Abbas AK. Functional responses and apoptosis of CD25 (IL-2Rα)-deficient T cells expressing a transgenic antigen receptor. J Immunol. 1997;158:3738-3745.
34. Sharfe N, Dadi HK, Shahar M, Roifman CM. Human immune disorder arising from mutation of the α chain of the interleukin-2 receptor. Proc Natl Acad Sci U S A. 1997;94:3168-3171.
35. - immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188:287-296.
36. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1998;10:1969-1980.
37. Papiernik M, Leite-de-Moraes M, Pontoux C, Vasseur F, Pénit C. Regulatory CD4 T cells: expression of IL-2Rα chain, resistance to clonal deletion and IL-2 dependency. Int Imunol. 1998;10:371-378.
38. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol. 1999;162:5317-5326.
39. + immunoregulatory T cells is antigen nonspecific. J Immunol. 2000;164:183-190.
40. + regulatory T cells down-regulate costimulatory molecules on antigen-presenting cells. Eur J Immunol. 2000;30:1538-1543.
41. - immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000;12:431-440.
42. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000;192:303-309.
43. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN. Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population, Eur J Immunol. 2001;31:1122-1131.
44. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001;193:1285-1294.
45. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001;193:1303-1310.